Pfizer Inc.: PharmaVitae Profile

Introduction

This analysis examines the historical and forecast performance for Pfizer in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits

* Gain insight into Pfizer's strategic outlook across the next 6 years* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights

Strategic insight into the prospects for Pfizer over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered

* Benchmark Pfizer's performance against key rivals in the prescription pharmaceutical sector* Assess how large scale M&A has shaped Pfizer's growth over the previous decade and how the Wyeth acquisition will impact growth through to 2015.* Analyse how the sustainability of Pfizer’s blockbuster model will come under significant pressure when Lipitor loses US patent exclusivity in mid-2011

[Studien Infos ausblenden]

Executive Summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2003–15
Financial performance, 2003–15
Pfizer: PharmaVitae forecasts at a glance
Strategic insight
Diversification strategy at heart of Wyeth M&A
Outlook – will Pfizer return to the M&A trail before 2015?
SWOT analysis
Strengths
Weaknesses
Opportunities
Threats
ABOUT THIS PROFILE
PharmaVitae Explorer database
Chapter structure
Quarterly update
Company introduction
Company sales
Company financials
Key products
Data sourcing
Analyst consensus
QUARTERLY NEWS UPDATE
Latest quarterly sales
Latest quarterly financial analysis
Q3 2010
Q2 2010
Latest comment
Q4 2010
Q1 2010
Latest prescription pharma product news
Latest corporate news
Q4 2010
Q3 2010
Q2 2010
Q1 2010
Q4 2009
Future product milestones
COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
M&A history
Warner-Lambert acquisition
Pharmacia acquisition
COMPANY SALES
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003–15
Product analysis
Product analysis, 2003–09
Product analysis, 2009–15
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2009-15
Core analysis, 2009-15
Expiry analysis, 2009-15
Launch/core/expiry configuration, 2009–15
Molecule type analysis
Externalization analysis
COMPANY FINANCIALS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09
Operating costs and profit analysis
Operating costs and profit analysis, 2002–08
Operating cost ratio and profit margin analysis, 2003–09
Operating cost ratio and profit margin analysis, 2009–15
Operating costs and profit analysis, 2009–15
KEY PRODUCTS
Overview
Prevnar
Enbrel
Bapineuzumab
Sutent
Tygacil
Lipitor
Celebrex
Viagra
Xalatan/Xalacom
Detrol/Detrol LA
APPENDIX
Abbreviations
Exchange rates

[Inhaltsverzeichnis ausblenden]